Sprint Bioscience AB (5JA1) AI Stock Analysis

0 Followers

Sprint Bioscience AB

(Frankfurt:5JA1)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Debt-free balance sheetA debt-free balance sheet reduces solvency and refinancing pressure, which is especially valuable for a biotechnology company funding uncertain development timelines. Rebuilt equity also provides a stronger financial base and greater flexibility to support operations or advance discovery programs.

Negative Factors

Declining TTM revenueA TTM revenue decline indicates that current profitability has not yet been matched by sustained top-line expansion. Without renewed revenue growth, earnings may remain dependent on project timing or mix, making it harder to establish a consistently compounding business trajectory.

Sprint Bioscience AB (5JA1) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 35.91M
Dividend Yield: ―
Average Volume (3M): 3,947
Price to Earnings (P/E): 5.8
Beta (1Y): 2.03
Revenue Growth: 177.26%
EPS Growth: ―
Country: Germany
Employees: 32
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Sprint Bioscience AB Business Overview & Revenue Model

Company Description

Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunoth...

Sprint Bioscience AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:5JA1 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SE:CANTA	83Outperform	SEK 395.00M	2.04	63.09%	―	―	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SE:ELIC	48Neutral	SEK 173.51M	-7.31	-56.09%	―	―	14.10%
SE:BINV	43Neutral	SEK 192.15M	-0.39	-128.54%	―	-83.67%	-50.29%
SE:IMMU	39Underperform	SEK 284.82M	-2.43	-18.05%	―	―	13.06%
SE:IVACC	39Underperform	SEK 237.55M	-2.23	-34.25%	―	-17.73%	18.97%

* Healthcare Sector Average

Performance Comparison

DE:5JA1 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:5JA1	Sprint Bioscience AB	0.33	0.29	700.00%
SE:BINV	BioInvent International AB	2.92	-26.98	-90.25%
SE:ELIC	Elicera Therapeutics AB	2.58	-2.68	-50.86%
SE:IVACC	Intervacc AB	0.67	-0.22	-24.78%
SE:IMMU	Immunicum AB	4.36	-1.30	-23.06%
SE:CANTA	Cantargia AB	1.39	-2.06	-59.77%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Sprint Bioscience AB AI Stock Analysis